Veterinarians have a new, innovative vaccine choice available for protection from the primary pathogen of canine infectious respiratory disease (CIRD). The vaccine, Bronchi-Shield® ORAL from Boehringer Ingelheim Vetmedica, Inc. (BIVI), recently has been approved by the USDA for use in dogs. This vaccine is unique because it is the first live, avirulent Bordetella bronchiseptica vaccine licensed to be administered orally to dogs.
Lorie R. North, associate director, pet vaccine marketing states, “BRONCHI-SHIELD ORAL offers the convenience of oral administration for mucosal absorption, making it one of the most innovative CIRD vaccines on the market. You simply squirt 1.0 mL of vaccine in the dog’s buccal cavity.
”According to Arne Zislin, VMD, technical manager veterinarian with BIVI, “BRONCHI-SHIELD ORAL has been proven in a challenge study to provide protection against the primary pathogen causing CIRD – B. bronchiseptica.
“Doctors have told us they like intranasal vaccines because they provide optimal immune responses, but doctors and their patients dislike having these vaccines given in the nose,” Zislin says. “So we’ve developed an easy-to-administer oral vaccine that is mucosally absorbed.”
Zislin goes on to say, “BRONCHI-SHIELD ORAL is made with PureFil Technology™ that exemplifies our commitment to quality and continuous improvement. PUREFIL TECHNOLOGY was first demonstrated in Duramune Lyme® vaccine with excellent feedback from veterinarians. BIVI is committed to finding new and innovative methods to provide our customers with products that are safe, effective and easy to use.
”Although vaccines that protect against CIRD are considered non-core by the American Animal Hospital Association Canine Vaccine Guidelines, many dogs are at risk. “When dogs come into contact, even casually on a walk, they may be at risk,” Zislin says. Veterinary practitioners should consider their at-risk patient populations and implement effective strategies to protect their patients.
BRONCHI-SHIELD ORAL is labeled as an aid in the prevention of disease caused by Bordetella bronchiseptica and is administered orally. Easy administration requires veterinarians to instill a 1.0 mL dose into the buccal cavity of healthy dogs eight weeks of age or older. Annual revaccination is recommended.
For more information about BRONCHI-SHIELD ORAL and how it can be used to provide effective, safe protection against the most common disease agent of CIRD complex, or about other innovative products produced by Boehringer Ingelheim Vetmedica, visit www.bronchi-shieldoral.com.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.